Physician profile
Philip W Corbin
NPI 1376538819
$8,938.84
in general payments reported to CMS, 2019-2025
50 companies · $1,649 in 2025
The $1,649 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,074 · 2020: $422 · 2021: $928 · 2022: $1,537 · 2023: $1,545 · 2024: $1,784 · 2025: $1,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,977.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,563.97 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $865.63 | 2019-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $781.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $724.53 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $617.06 | 2019-2025 | |
| Glaxosmithkline, LLC. | $342.94 | 2019-2025 | Trelegy Ellipta, Bexsero, Penmenvy |
| Corium, LLC | $306.53 | 2023-2025 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $274.99 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $270.95 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.21 | 2019-2025 | Jardiance, Ofev |
| Astellas Pharma US INC | $250.69 | 2019-2024 | Veozah, Myrbetriq |
| Amgen INC. | $225.96 | 2019-2024 | Evenity, Prolia |
| Sumitomo Pharma America, INC. | $216.99 | 2023-2025 | Gemtesa |
| Exact Sciences Corporation | $153.03 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $147.64 | 2019-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Corbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.